Funding cuts are widening the gap for early-career researchers. Binaytara's Binay Shah explains how small seed grants can keep promising studies alive.
- Who's Wearing The Patient Recruitment Hat When Your Trial Decisions Are Made?
- Why Radioligand Therapy Studies Look Nothing Like Standard Oncology Phase 1s
- Years Before Clinical Trials: The Decisions That Shape The Future Of Academic Cancer Discoveries
- Two Parallel Trials, A Potential New Option For Protection From COVID-19
- Firsthand Findings: How Incannex Is Designing Trials That Support Regulatory Approval
- The 2026 Pharma R&D AI Sourcing Map: Partnerships, Concentration, Inflection
- Lupus Researchers Now Have A Three-Pillar RWD Platform To Support Discovery And Development
GUEST COLUMNISTS
-
The 2026 Pharma R&D AI Sourcing Map: Partnerships, Concentration, Inflection
A Beroe analysis of 2026 pharma AI deals shows discovery still dominates, suppliers are consolidating, and clinical development is the next AI sourcing frontier.
-
Lupus Researchers Now Have A Three-Pillar RWD Platform To Support Discovery And Development
Lupus Nexus unites a registry, biorepository, and data exchange to give researchers longitudinal real-world data without building the infrastructure from scratch.
-
Novel Science, Familiar Regulatory Pathways: Inside Tonix's Clinical Development Strategy
Tonix CEO Seth Lederman, MD, explains how the company pairs novel science with proven regulatory paths across fibromyalgia, depression, and Lyme disease.
-
As U.S. Trial Share Slips, A Coalition Maps A Path To Broader Patient Access
Milken Institute's Kristin Schneeman explains how a new action plan could broaden patient access in the U.S. — and what sponsors and policymakers can do now.
-
A Window Into Aging: Why Skin Is the First Test For RLS-1496
Rubedo’s Marco Quarta explains how patient selection, controls, biopsies, and biomarkers shaped early RLS-1496 trial protocols.
-
Brazil's Regulatory Transformation: Building And Supporting Sites Beyond The AMCs
Our expert chat about Brazil’s clinical research transformation concludes with SBOC President-elect Fabio Franke, who explores building sustainable trial capacity beyond the country’s major AMCs.
-
Brazil's Regulatory Transformation: Expanding Clinical Trial Participation
A discussion of Brazil’s clinical research transformation continues as this Q&A series turns to Maiko L. Tonini, Ph.D., of Brazil’s Ministry of Health, to explore expanding clinical trial participation.
-
Brazil's Regulatory Transformation: A New Era For Clinical Development
Brazil’s clinical research transformation takes center stage as this new Q&A series opens with Interfarma CEO and former ANVISA director Renato Porto.
CLINICAL TRIAL WHITE PAPERS
-
Five Ways Centralized Trial Finance Improves Site And Patient Satisfaction
Centralizing payments and logistics improves transparency, accelerates reimbursements, and supports better site performance and patient retention in clinical trials.
-
Digital Twins: From Protocol Design to Predictive Study Execution9/14/2026
A growing generation of AI-enabled digital twin approaches offers a new path. Instead of treating the protocol as a static document, organizations can model it as a dynamic system.
-
4 New Approvals In Q3 Across Gene, Cell, RNA Therapies11/13/2025
Q3 2025 brought notable progress across the gene, cell, and RNA therapy landscape, marked by four new global approvals. While regulatory progress continued, clinical development activity slowed.
-
Overcome Patient-Level Access Barriers For New Medicine3/23/2026
Explore market access from the patient’s perspective and identify five aspects of how people get hold of medicine that should inform commercialization.
-
Reimagining Medical Monitoring In Clinical Research4/11/2025
Clinical trials are undergoing a transformative shift driven by evolving regulations, advanced technologies, and decentralized methodologies.
-
How Remote Pharmacy Monitoring Improves Trial Compliance6/10/2026
Explore how leading IDS pharmacies are using remote monitoring workflows and digital accountability systems to improve accuracy, reduce site burden, and maintain audit readiness.
CLINICAL TRIAL APP NOTES & CASE STUDIES
-
Nectin 4 Biomarker Testing For Oncology Clinical Programs11/6/2026
No validated test existed for a key tumor biomarker. See how a tissue-staining assay was built, validated, and scaled to select the right patients for a cancer trial.
-
NDA Success Strategy: Using Non-US Clinical Data In An NDA Submission8/12/2025
A sponsor acquiring a therapeutic asset from an overseas company sought assistance when including foreign clinical trial dat,a generated outside a U.S. IND, in a New Drug Application (NDA).
-
Pioneering The End-To-End Decentralized Trial Experience4/16/2025
This collaboration highlights the potential of decentralized clinical trials (DCTs) to transform trial execution, as well as offering a replicable model for future research.
-
Participant Support In Oncology Trials With Cachexia-Related Burden4/21/2026
Coordinated travel, reimbursements, and visit logistics for oncology participants experiencing fatigue, weight loss, and reduced mobility, helping reduce dropouts and keep people engaged.
-
Redefining Accessibility For Pediatric Patients9/24/2025
Explore how meeting patients where they are can redefine what successful pediatric trial delivery looks like.
-
No More Swiss Holes: Filling The Gaps In Clinical Trial Disclosure1/14/2026
This use case shows how sponsors can gain clarity on disclosure requirements when entering a new country.
NEWSLETTER ARCHIVE
- 11.18.26 -- Lab Logistics: Delivering The Complex Without Compromise
- 11.18.26 -- Sponsors Can Drown In Data As Patient Diversity Gaps Persist
- 11.17.26 -- From Consent To TMF: Tech Built Around The Realities Of Site Work
- 11.16.26 -- Care Gaps, Dropout, And Data Variability: Where Trials Quietly Break Down
- 11.14.26 -- Best Of October
RECRUITMENT AND DIVERSITY
This section includes some helpful resources regarding patient recruitment and diversity in clinical trials, including this link to the FDA's guidance on diversity action plans.
-
Recruitment problems can start long before actual recruitment. Who is making sure your team gets ahead of those challenges?
-
Lupus Nexus unites a registry, biorepository, and data exchange to give researchers longitudinal real-world data without building the infrastructure from scratch.
-
Milken Institute's Kristin Schneeman explains how a new action plan could broaden patient access in the U.S. — and what sponsors and policymakers can do now.
FOCUS ON PATIENTS
-
Milken Institute's Kristin Schneeman explains how a new action plan could broaden patient access in the U.S. — and what sponsors and policymakers can do now.
-
Clinical trial patients may need care outside of the trial protocol. Discover how closing information gaps can protect safety, trial participation, and data integrity.
-
Can early APG-157 treatment control head and neck cancer without delaying curative care? A Phase 3 trial puts timing, safety, and outcomes to the test.
EDITORIAL COLLECTIONS
Take a deep dive into the issues shaping clinical research today with our curated Editorial Collections. Each collection features expert insights and practical strategies addressing today’s biggest challenges in clinical trial planning and execution.
More Editorial Collections
